There are concerns about the state of CRISPR companies. Some reports suggest that CRISPR-based treatments are showing promise, such as a treatment for a rare disease that reduced swelling attacks in a trial. However, others indicate that biotech investors may need to temper their expectations for CRISPR science and that alternative gene editing tools, like TGEE, could potentially emerge as competitors.